WHAT YOU NEED TO KNOW Recently, I-MAK released a new report that outlines how AbbVie abuses the U.S. patent system to stave off competition for their critical cancer drug, Imbruvica.  This analysis was also covered by STAT News which showed AbbVie could have its patents on Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for […]

Continue Reading

WASHINGTON, DC: In case you missed it, STAT today highlighted a new analysis that shows AbbVie could have its patents on cancer drug Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for the cancer treatment drug.  As I-MAK details in a new report, this move would prevent cheaper generic alternatives from entering the market […]

Continue Reading

WASHINGTON, DC: In case you missed it, Politico today highlighted the significant drug pricing hikes made by big pharmaceutical companies as millions of patients struggle to access affordable drugs amidst the coronavirus pandemic.  This year alone, big Pharma companies conducted hundreds of new price increases on patients which would appear to confirm the fears of many Americans.  […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse (CAPA) along with Niskanen Center, Engine, R Street Institute and other public and private interest groups signed on to a letter sent to the House and Senate Judiciary Committees encouraging them to exercise their oversight authority to investigate procedural changes recently made by the Patent […]

Continue Reading